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Background: Aberrant DNA methylation marks are potential disease biomarkers, and detecting both total genomic
and gene-specific DNA methylation can aid in clinical decisions. While a plethora of methods exist in research,
simpler, more convenient alternatives are needed to enhance both routine diagnostics and research.
Results: Herein, we describe colorimetric assays using methyl-binding domain (MBD) proteins for rapid and
convenient evaluation of total genomic and gene-specific methylation from 50 ng or less DNA input in under 2 h.
As little as 5 % methylation differences can be detected and are enhanced by a novel MBD protocol for improved
specificity. Our assays could differentiate naïve from de-methylating drug-treated cells and detect the presence of a
methylated prostate cancer biomarker in the urine. Finally, the assay was evolved onto disposable screen-printed
electrodes for convenient detection of gene-specific methylation in urine.
Conclusions: Rapid MBD-based colorimetric and electrochemical approaches to detect DNA methylation from
limited samples were successfully demonstrated and applied to clinical samples. We envision that the ease, low
sample requirements and speed of these assays could have both clinical and research-wide applications.
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Aberrant epigenetic changes in DNA are potential dis-
ease biomarkers [1–3]. A form of epigenetic change is
the methylation of the cytosine (5mC) in cytosine/guanine
dinucleotides (CpG), particularly in CpG islands (CGI) of
regulatory regions that function to regulate cellular pro-
cesses [1–3]. Azanucleoside drugs such as 5-aza-2′-deoxy-
cytidine (5-Aza) have been used therapeutically with some
success to reactivate silenced genes in epigenetic diseases
[4–6]. In addition, genome-wide hypomethylation is also
associated with tumorigenesis [2, 3] and hence may be
useful as an early screening strategy for cancer. While hy-
pomethylation is associated with tumorigenesis, regulatory
sequences at specific loci, such as that of tumour suppres-
sor genes, are hypermethylated and detection of which
are potentially useful in stratifying patient cohorts and* Correspondence: j.wee@uq.edu.au; m.trau@uq.edu.au
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however, detect DNA methylation via bisulfite conver-
sion [8, 9] of DNA followed by some form of sequen-
cing [10–13]. To avoid the problems associated with
bisulfite conversion, affinity capture approaches, such
as methyl-binding domain (MBD) proteins or anti-
bodies raised against 5mC, have been adapted to Next
Generation Sequencing [14] platforms or other optical
detection methods for both genome-wide [15, 16] and
gene-specific [17] applications. Useful, simpler, more
convenient methods to detect both genome-wide and
gene-specific methylation are still lacking and would be
useful for both routine diagnostics and research.
MBD enrichment approaches are useful and conveni-
ent because they avoid the limitations of bisulfite con-
version while being very highly specific for 5mC on
native double-stranded DNA but not hydroxymethylated
(5hmC) or unmethylated DNA [18]. Unfortunately, MBD
enrichment approaches are limited by their difficulty in
quantifying methylation levels and typically quantitative
PCR (or sequencing) is used to measure enrichment levelsle distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in
operly credited. The Creative Commons Public Domain Dedication waiver
/1.0/) applies to the data made available in this article, unless otherwise stated.
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itionally, the stringency of MBD enrichment reduces
with limiting DNA inputs and various strategies includ-
ing high-salt buffers [19] and alternative MBD enzymes
[20] have been devised. Nonetheless, one is still able to
infer, with very high stringency, the degree/density of
methylation based on the buffer conditions required to
recover enriched DNA [14, 19]. In short, the methylation
outcomes derived from MBD approaches are generally
binary, i.e., yes/no calls and therefore, ideal for identifying
highly differentially methylated regions (HDMRs).
Colorimetric readouts are also popular in molecular
diagnostics because they can be evaluated with the
naked eye and have the option for (semi)quantification.
One popular colorimetric system is the horse radish per-
oxidase HRP/H2O2 system coupled to a chromogen e.g.,
3,3′,5,5′-tetramethylbenzidine (TMB) substrate to gener-
ate a coloured by-product to signal the presence of a
biomolecule, (HDMRs in this case). Herein, we describe
MBD-based colorimetric assays for rapid, naked-eye
evaluation of either overall genome-wide or gene-specific
methylation detection. In addition, we also describe a
novel method for rapid yet highly specific MBD enrich-
ment from low nanogram amounts of DNA input for loci-
specific applications that was subsequently applied to
urine DNA derived from prostate cancer patients. Finally,
since TMB is electrochemically active [21], we adapted
our assay onto commercially available screen-printedFig. 1 Assay schemes. a Strategy for total genomic methylation. Genomic
a fill-in reaction with Klenow polymerase and biotin-dNTPs. MBD magnetic
evaluation is mediated by SA-HRP which recognizes the biotin on enriched
DNA is RE digested and methylated DNA is selected via MBD enrichment. Ge
to generate biotin-DNA polymers which are in turn selected for with SA magelectrodes as a potential alternative electrochemical ap-
proach for detecting DNA methylation. To the best of our
knowledge, these are the first demonstrations of colori-
metric and electrochemical evaluations of DNA methyla-
tion via MBD and may have wide applications in both
research and diagnostics.
Results and discussion
The MBD/HRP assays
To realize a simple MBD-based approach for naked-eye
detection of DNA methylation, we first developed a
proof-of-concept method for overall genomic methyla-
tion (Fig. 1a). Then, based on a similar strategy, the
assay was extended to loci-specific targets (Fig. 1b). Both
approaches began with an enzymatic digestion of gen-
omic DNA (gDNA) to fragment and reduce the com-
plexity of gDNA for optimal MBD enrichment. For
genome-wide analysis (Fig. 1a), digested gDNA frag-
ments were then enzymatically labelled with biotin with
a “fill-in” reaction to generate a DNA/biotin polymer
(see Methods for detailed procedure). MBD2a (a mem-
ber of the MBD protein family) that had been conju-
gated to a paramagnetic particles was then used to select
for methylated DNA. The enriched biotin-labelled meth-
ylated DNA was, in turn, recognized by streptavidin-
conjugated horse radish peroxidase (SA-HRP) via the
biotin/streptavidin interaction. Finally, methylation levels
were then visually evaluated via the HRP-mediatedDNA is restriction enzyme (RE) digested, enzymatically biotinylated via
beads are then used to select for methylated DNA. Colorimetric
methylated DNA. b Strategy for gene-specific methylation. Genomic
ne-specific isothermal amplification is then performed with biotin-dNTP
netic beads and SA-HRP for colorimetric evaluation
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intensity of the developed colour was proportional to
the amount of captured DNA and thus the level of
methylation.
To enable gene-specific applications (Fig. 1b), digested
DNA was first subjected to a novel protocol for rapid
yet highly specific MBD enrichment from limiting sam-
ples (details in a later section). This was then followed
with an isothermal amplification of the desired region
with biotin-deoxynucleotides (dNTPs) to generate poly-
mers of biotin/DNA which then served as substrates for
the HRP/TMB colorimetric reaction and therefore indi-
cating the presence of a HDMR.
Detecting genome-wide methylation
To demonstrate the feasibility of genome-wide methyla-
tion assay, we first tested if we could detect 200 pg of
119-bp synthetic sequence at various levels of methyla-
tion (Fig. 2). Figure 2a shows the positive relationship
between methylation and chromophore intensity (mea-
sured as absorbance at 650 nm). Near baseline signals
from the 0 % methylated sample indicates the high specifi-
city of the assay. Consistent with the literature [18], the
MBD assay was also insensitive to hydroxymethylated
DNA under the current assay conditions (Additional file
1: Figure S2). To determine the sensitivity of the assay i.e.,
the smallest detectable change in percent methylation, we
compared the signal generated at 2, 5 and 10 % methyla-
tion with that of the 0 % methylated sample. Since signal
at 5 % was significantly higher (t test p < 0.05), we con-
cluded that the assay was sensitive to at least 5 % methyla-
tion changes. In contrast, 10 % or more methylated
samples are easily differentiated by eye from the unmethy-
lated control (Fig. 2b). Similar results were also seen with
in vitro methylated whole genome amplified DNA (M-
WGA, Additional file 1: Figure S1) where as little as
37.5 pg of methylated DNA could be detected. In contrast,
current commercial ELISA-based approaches advertise a
200-pg or more detection limit. Finally, we evaluated the
stability of the assay (Additional file 1: Figure S2) andFig. 2 Total methylation assay performance. a Calibration plot of
HRP/TMB colorimetric response with respect to changes in amount
of methylated DNA. Error bars represent SD, n = 3. b Photo of HRP/
TMB reactions used to generate the calibration plotfound that the inter- and intra-assay coefficient of variabil-
ity (CV) were 7.9 % (n = 3) and 5.2 % (n = 6), respectively,
indicating good reproducibility.
While we demonstrate a wide dynamic range of
methylation in this study, the method may be tuned to
narrower ranges by adjusting the buffer conditions to
detect meaningful levels of methylation over normal
levels. However, given the current limits in detection
and reproducibility, the assay would more likely be
suited to detect differential methylation changes of 10 %
or more in a clinical setting.
Total DNA methylation is traditionally detected by
HPLC [22] and mass spectrometry (MS) [23] methods.
While our MBD assay uses less starting material, it is
difficult to directly compare the methylation-based ana-
lytical performances. This is because both HPLC and
MS approaches consider all cytosines in the genome
whereas our assay is an enrichment approach that only
considers a subset of cytosines and therefore a different
measure of methylation. Nonetheless, compared to the
published data in a previous MBD/flow cytometry study
[16], the current approach had similar analytical per-
formance but only required a fraction of the processing
time (2 versus 24 h). Finally, in comparison to the pub-
lished data in a recent study via a proximity oxygen
channelling chemistry platform [15], both approaches
had similar performance in detecting methylated DNA.
However, the oxygen channelling platform requires very
specialized equipment for detection whereas the colori-
metric strategy described herein does not.
Next, we sought to demonstrate a potential clinical ap-
plication in tracking response to de-methylating therapy.
To this end, the assay was performed using genomic
DNA derived from human cancer cell lines before and
after 5-Aza treatment and with M-WGA and unmethy-
lated WGA DNA (U-WGA) as controls (Fig. 3). We
could clearly distinguish between M-WGA and U-WGA
and, as expected, differentiate DNA samples before andFig. 3 Differentiating between 5-Aza-treated and untreated cells.
a Colorimetric response of highly methylated M-WGA DNA, naïve
Jurkat cells and Jurkat cells after 5-Aza treatment relative to
unmethylated U-WGA control. Error bars represent SD, n = 3. b Photo
of the colorimetric assay from the corresponding experiments
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such as HPLC and MS, while useful, have difficult sample
preparation and require high amounts of input DNA (mi-
crograms) [24] thus severely limiting its adoption in rou-
tine diagnostics. In contrast, our approach required at least
one order of magnitude lesser DNA (~50 ng) of starting
material, had similar performance to commercial ELISA-
based assay and required approximately 2 h to complete.
Improved MBD protocol for highly specific enrichment
from limited DNA input
A potential limitation of MBD enrichment strategies is
non-specific capture of unmethylated DNA. This prob-
lem is especially pronounced with low DNA input be-
cause of increased background from non-specifically
captured unmethylated DNA and is further confounded
when coupled to an exponential DNA amplification for
gene-specific applications. Various strategies to alleviate
this problem include multiple methylation-sensitive re-
striction digestion [25], exotic MBD complexes [20], high-
salt-binding buffers and incubation at low temperatures
[19]. While these approaches improved specificity, their
long overnight incubation may not be feasible for applica-
tions requiring fast turnovers e.g., routine diagnostics.
Nonetheless, the results of these studies suggested
that when MBD was in excess, as in the case of low
sample input, MBD non-selectively bound both methyl-
ated and unmethylated DNA. Hence, we hypothesized
that increasing the DNA to MBD ratio could restoreFig. 4 Improved MBD enrichment. a Gel electrophoresis image of RPA amp
protocol, increased salt with 1.25× buffer, and with 1.25× buffer supplemen
improvement in enrichment. Error bars represent SD, n = 3. M M-WGA, U Uthe selectivity of MBD for methylated DNA. One pos-
sible way to increase the DNA/MBD ratio is to intro-
duce exogenous carrier/blocking DNA, such as salmon
sperm DNA, to sequester free MBD.
To this end, we arbitrary added 50 ng of salmon sperm
DNA to 50 ng of human WGA DNA and performed the
MBD enrichment. Under this condition, minimal non-
specific enrichment of U-WGA was detected with minimal
lost in performance for M-WGA based on subsequent iso-
thermal amplification and electrophoresis analysis (Fig. 4),
thus supporting our hypothesis. Using densitometry, the
signal to noise (M-WGA and U-WGA, respectively, post-
MBD enrichment) with our approach was 14.2-fold which
was a marked improvement over the default manufacturer
protocol (2.1-fold) or just an increase in buffer salt concen-
trations (3.1-fold). In short, these results confirmed our hy-
pothesis that an increased DNA/MBD ratio could enhance
specificity. To our knowledge, this is the first description
of exogenous blocking DNA being used to improve strin-
gency of MBD-based assays. In contrast to the long over-
night protocols previously described in the literature,
our approach required only a 15-min MBD incubation
(Additional file 1: Figure S3). This rapid, simple and
low-cost solution may be useful for applications where
sample DNA is limited.
Detecting GSTP1 methylation with the MBD/HRP assay
Confident of the stringency displayed by our MBD enrich-
ment protocol, we next turned our attention to designinglifications after MBD enrichment under the default manufacturer’s
ted with 50 ng of blocking DNA. b Graph showing the relative
-WGA, NoT no template control
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ant HDMR biomarker of prostate cancer [26, 27]. Cur-
rently, the methylation status of GSTP1 is the only
FDA-approved methylation biomarker undergoing clin-
ical trials [28] and is usually detected by head loop PCR
[29]. While potentially useful, the approach has various
limitations such as the need for bisulfite conversion
and complicated primer design. Simpler assays are hence
needed to facilitate widespread adoption. The MBD/HRP
approach described herein may fulfil this need.
As shown in Fig. 5, the assay could detect as little as a
5 % methylated sample. As a control, we also tested the
input DNA prior to MBD enrichment. Since the amount
of input DNA can affect the resultant amount of amplifi-
cation, we therefore propose that to improve accuracy,
the ratio of the signal generated post-MBD to pre-MBD
(initial DNA input) be used to generate a methylation
score (Fig. 5c). This method also had good reproducibil-
ity with intra-assay CV (n = 8) of 7.8 % and inter-assay
CV (n = 4) of 9.1 % (Additional file 1: Figure S4).
To demonstrate feasibility on complex biological sam-
ples, we first assayed two cancer cell lines (Fig. 6a–c).
DuCap cells were found to be methylated but less so for
HeLa cells. We then assay Jurkat cells before and after
5-Aza treatment (Fig. 6d–f ). As expected, GSTP1 was
de-methylated significantly after 5-Aza treatment. Finally,
the method was then applied to four DNA samples de-
rived from the urine of metastatic, castration-resistant
prostate cancer patients (Fig. 6g–i). Three of the four pa-
tients were found to be highly methylated at the GSTP1
gene promoter. Together, these results indicated that the
MBD/HRP colorimetric assay may be a useful alternative
for detecting GSTP1 methylation in the clinic.Fig. 5 Performance of gene-specific assay for 100, 50, 25, 5, and 0 % methy
and photo of HRP/TMB reactions. Top: post-MBD enrichment. Bottom: inpu
measurements. Blue: post-MBD enrichment. Red: input control. c Calibrati
represent SD, n = 3The assay was further extended to the ESR1 gene pro-
moter which is also aberrantly methylated in cancers
[30]. To this end, we assayed Jurkat cells before and after
5-Aza treatment with M-WGA and U-WGA as specifi-
city controls (Additional file 1: Figure S5). As expected,
ESR1 was de-methylated in the 5-Aza-treated cells com-
pared to naïve Jurkat cells. The de-methylation of both
GSTP1 and ESR1 in 5-Aza-treated cells were consistent
with the genome-wide hypomethylation observed in Fig. 3.
Based on the data shown here, a MBD/HRP-based ap-
proach may be useful for both total genomic and gene level
methylation. However, a known limitation of all MBD-
based approaches is the inability to provide methylation in-
formation at individual CpGs. In addition, MBD is also not
able to provide 5hmC information [18]. While methods
exist for 5hmC, there is no simple single-step method be-
sides HPLC and/or MS able to simultaneously interrogate
both 5mC and 5hmC. Nonetheless, this MBD/HRP ap-
proach could be adapted to an analogous assay for 5hmC
using affinity reagents currently available for 5hmC [31].
Adapting to an electrochemical assay using disposable
screen-printed electrodes
The benefits of an electrochemical assay include
miniaturization, improved performance and reduced
cost [32–34]. Since TMB is electrochemically active
[21], we had the potential to adapt our MBD/HRP
assay onto commercially available screen-printed car-
bon electrodes (SPCE) as a convenient alternative readout
platform (Fig. 7a). As a proof of concept, we applied the
electrochemical assay on the same four prostate cancer
samples. As expected, methylation scores were identical to
that derived via spectrometry (Fig. 7b and Additional filelated DNA samples. a Gel electrophoresis images of RPA amplifications
t controls i.e., before MBD enrichment. b Corresponding absorbance
on plot of HRP/TMB response to methylation changes. Error bars
Fig. 6 GSTP1 methylation in samples. Detecting GSTP1 methylation in cell lines (a–c), cells before and after 5-Aza treatment (d–f) and in prostate
cancer patients (g–i). a, d, g Gel electrophoresis images of RPA amplifications and photos of HRP/TMB reactions. b, e, h Corresponding
absorbance measurements. Blue: post-MBD enrichment. Red: input control. c, f, i Normalized HRP/TMB response (score) to methylation
changes. Error bars represent SD, n = 3
Fig. 7 Electrochemical detection of GSTP1 methylation in urine DNA. a Conceptual schematic of the electrochemical detection of HRP oxidized
TMB (TMBox). Photo of disposable SPCE is shown. On the electrode surface, TMBox is reduced back to TMBred. The resulting current is proportional
to the amount of TMBox. b Current measurements of the four patient samples. Blue: post-MBD enrichment. Red: input control. c Comparison of
methylation scores for patient samples determined electrochemically (blue) and by absorbance (red). Error bars represent SD, n = 3
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an electrochemical MBD-based assay for detecting DNA
methylation in urine (and possibly other bodily fluids), it
also demonstrated that our methylation assay was readout
agnostic and may be adapted to other readout methods
for added convenience as a diagnostic assay. To the best
of your knowledge, this is also the first electrochemical
assay for methylation detection via MBD.
Conclusions
In conclusion, we have developed simple and rapid ap-
proaches to detect total genomic DNA methylation and
at specific gene sequences. The assays were first devel-
oped on a colorimetric readout for naked-eye evaluation
and subsequently onto electrochemical approach for
convenient diagnostic and research applications. We also
described a novel MBD protocol with improved strin-
gency by exploiting the competitive binding of non-
human carrier DNA to sequester excess MBD. The high
sensitivity, ease and low sample requirements of our ap-
proach may be useful for routine diagnostics and a wide
range of applications unlike traditional methods.
Availability of supporting data
The data sets supporting the results of this article are in-
cluded within the article and its additional files.
Methods
DNA preparation
To demonstrate the feasibility of the assay, a 119-bp
DNA fragment model system over the GSPTP1 gene
was PCR amplified using standard procedures using the
Kapa2G Robust PCR kit (KapaBiosystems, USA) with
forward and reverse primers (AACCCCCTTATCCCTCC
GTCGTGTGGCTTTTAC and AAACAGGTTCCTCCG
AAGATTTCACACAACACT, respectively (Integrated
DNA Technologies, Australia). Amplicons were then
purified using QIAquick Gel extraction kit (Qiagen,
Australia). To generate methylated sequences, amplicons
were treated with SssI methyltransferase (New England
Biolabs, USA) overnight as recommended by the manu-
facturer and purified using the Agencourt AMPure XP
kit (Beckman Coulter, Australia). An aliquot of the
SssI-treated DNA was used to evaluate the methylation
conversion efficiency by digestion with the methylation-
sensitive HpaII restriction enzyme (New England Biolabs,
USA). Only reactions with no detectable digestion via gel
electrophoresis were used in downstream experiments.
Finally, the amplicons were treated with 5 μM biotin-
14-dUTP (Thermo Fisher, Australia) and terminal deox-
ynucleotidyl transferase (TdT, New England Biolabs,
USA) as recommended by the manufacturer.
WGA DNA was generated using the REPLI-g Ultra-
Fast Mini kit (Qiagen, Australia) and purified using theDNeasy Blood and Tissue kit (Qiagen, Australia). An ali-
quot of WGA DNA was then treated with SssI methyl-
transferase overnight and purified to generate highly
methylated genomic DNA (M-WGA). An aliquot of the
SssI-treated DNA was used to evaluate the methylation
conversion efficiency by digestion with the methylation-
sensitive HpaII restriction enzyme (New England Bio-
labs, USA). Only reactions with no detectable digestion
via gel electrophoresis were used in downstream experi-
ments. Genomic DNA from Jurkat cells representing be-
fore and after 5-aza-2′-deoxycytidine treatment were
purchased from New England Biolabs (NEB).
HeLa and DuCap cells were purchased from ATCC and
cultured according to the manufacturer’s instructions.
gDNA was extracted using the DNeasy Blood and Tissue
kit. Thirty millilitres urine samples from prostate cancer
patients were collected with the relevant ethics approval
from The University of Queensland Institutional Human
Research Ethics Committee (Approval No. 201400012)
and processed within 5 h with the ZR Urine DNA Isola-
tion Kit (Zymo Research, USA).
For total genomic methylation studies, 50 ng of gDNA
(both WGA and cell line derived) was enzymatically
digested with the endonucleases DpnII and MseI (7.5 units
each, NEB) at 37 °C in a 20-μL reaction supplemented
with the NEB Buffer 3.1 system to generate <1000 bp
DNA fragments with 5′ overhangs. After 30 min, the reac-
tion was supplemented to a final volume of 25 μL with 5
units of Klenow fragment (3′→5′ exo-) DNA polymerase
(NEB, USA) and 5 μM of biotin-14-dUTP, dATP, dGTP
and dCTP and incubated at 37 °C for another 30 min to fill
in the overhangs and biotinylate the fragmented DNA. The
reactions were then heat inactivated at 75 °C for 20 min.
For gene-specific applications, 50 ng of gDNA was
digested with MseI and MluCI (NEB, USA) instead at
37 °C for 30 mins in a 20-μL reaction supplemented
with the NEB CutSmart Buffer system.
Total genomic methylation assays
For total genomic methylation studies, digested gDNA
reactions were first diluted tenfold in water. One micro-
litre (i.e., 200 pg of DNA) was then used in the MBD/
HRP assay to estimate levels of methylation. MBD-
modified magnetic beads (NEB, USA) were prepared and
used as recommended by the manufacturer. To enrich
for methylated DNA, the provided 1× MBD buffer was
supplemented with 600 mM NaCl. After a 15-min incu-
bation with DNA targets, the MBD beads were isolated
with a magnet and the supernatant was removed. The
MBD beads were then resuspended in 20 μL of 1/1000
HRP solution (BD Biosciences, Australia) in 1× MBD
buffer for 10 mins. The MBD beads were then washed
four times with 1× MBD buffer. Finally, 100 μL of 1-Step™
TMB substrate solution (Thermo Scientific, Australia) and
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30 min on the EnSpire® plate reader (Perkin Elmer,
Australia). Absorbance values at 20 min were used in sub-
sequent data analysis.
Gene-specific assays
For gene-specific applications, 19 μL of digested DNA
was used for MBD enrichment in a modified protocol.
Briefly, one tenth of the recommended MBD/bead mix
was used in a 100-μL reaction. MBD buffer (1×), MBD
buffer (1.25×) or MBD buffer (1.25×) supplemented with
50 ng of salmon sperm DNA (Sigma Aldrich, Australia)
was used for a 15-min MBD enrichment step at 4 °C.
After three 5-min washes with 1× MBD buffer, the cap-
tured DNA was eluted in 5 μL 2.5 M NaCl solution. To
purify the enriched DNA for downstream amplification,
10 μL of Agencourt AMPure XP bead solution was
added to the same tube and purification proceeded as
recommended by the manufacturer. The purified DNA
was finally eluted in 20 μL water. The remaining 1 μL of
digested DNA was diluted tenfold in water and used as
input controls in subsequent amplifications.
To detect gene-specific methylation, the isothermal re-
combinase polymerase amplification [35] (RPA, TwistDx,
UK) was employed to amplify the GSTP1 locus with
primers described above in a modified RPA protocol.
Briefly, 1 μL of gDNA from the above step was used for
each 12.5 μL RPA reaction supplemented with 10 μM
biotin-14-dUTP and 7 mM MgOAc at 37 °C for 15 min.
After amplification, 12.5 μL of Agencourt AMPure XP
bead solution was used to remove excess biotin and pur-
ify amplicons. The purified amplicons were eluted in
15 μL of water where 3 μL was subjected to gel electro-
phoresis to verify amplification.
GSTP1 primers were as described earlier. ESR1 for-
ward and reverse primers were GTTCGTCCTGGGACT
GCACTTGCTCCCGTC and AGATGCTTTGGTGTGG
AGGGTCATGGTCATGGT, respectively.
To detect amplicons colorimetrically, 1 μL of purified
amplicons was reacted with 20 μL SA-HRP (1/2000 di-
lution in 1× PBS) and SA magnetic beads (1/20 dilution
in 1× PBS, NEB) for 5 mins. After collecting DNA-
bound beads with a magnet and three 1× PBS washes,
50 μL of TMB substrate solution was allowed to react
with the captured HRP and absorbance readings were
taken after a 15-min incubation.
Electrochemical assay
To enable an electrochemical readout, 50 μL of 0.5 M
H2SO4 was used to stop the HRP/TMB reaction after 15
mins and to convert TMB to its electrochemically active
form [21]. Fifty microlitres of the resulting TMB solution
was added onto screen-printed electrodes (CH Instru-
ments, USA) and electrochemical response was detectedusing ampometry at 150 mV over 30s on a potentiostat
(CH Instruments, USA). Current response at 10 s was
used for subsequent analysis.
Additional file
Additional file 1: Colorimetric detection of both total genomic and
loci specific DNA methylation from limited DNA inputs. Figure S1.
Total genomic methylation assay. Figure S2. Total genomic assay
specificity and variability assessment. Figure S3. Effect of MBD incubation
time on enrichment performance. Figure S4. Gene specific assay
variability assessment. Figure S5. Detecting methylation at the ESR1
gene. Figure S6. Representative ampometry profiles of the four prostate
cancer samples (P1 to P4) used in this study.
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